MAPT and Alzheimer disease: Specific biomarkers of AD, Aβ, and Tau could be detected on positron emission tomography (PET) or in cerebrospinal fluid (CSF), which are expensive, invasive, and limiting widespread application clinically (Verberk et al., 2018).